Clinical Trial of NAC in Asthma

Stopped early · Phase 4 · Has a placebo group

Conditions studied: Asthma

In brief

This study evaluates 20% n-acetylcystine (NAC) in the treatment of moderate-to-severe asthma that is complicated by mucus in the airway, as determined by CT imaging. The study is a crossover design, which means that half the study participants will get 20% NAC in the first 7-day treatment period and placebo in the next 7-day treatment period; and the other half will get placebo in the first 7-day treatment period and 20% NAC in the next 7-day treatment period.

Key facts

Study ID
NCT02605824
Run by
University of California, San Francisco
People needed
1
Starts
2016-03-01
Expected to finish
2017-12-01
Last updated by the study team
2019-08-20

Who can join

Age: 18 and older, up to 70. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.